Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Pancreatic Neoplasms 1 Mesothelioma, Malignant 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 28 Pemetrexed 24 pembrolizumab 12 Nivolumab 10 Carboplatin 9 atezolizumab 7 Gemcitabine 7 Cyclophosphamide 7 durvalumab 6 Drug Therapy 6 sodium thiosulfate 5 Radiotherapy, Intensity-Modulated 5 tremelimumab 4 aldesleukin 4 Radiotherapy 4 Interleukin-2 4 sargramostim 3 Vinorelbine 3 Platinum 3 Photochemotherapy 3 Ipilimumab 3 Doxorubicin 3 Dihematoporphyrin Ether 3 Chemotherapy, Adjuvant 3 Cerebral Decortication 3 vatalanib 2 regorafenib 2 niraparib 2 lenvatinib 2 cemiplimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Mesothelioma, Malignant × bemcentinib × Clear all

NCT03654833 2023-03-14

MiST

University of Leicester

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡